Clinical Progress on Bortezomib in the Treatment for Multiple Myeloma
TAN Ya-min, HUANG He (The Affiliated First Hospital of Medical College, Zhejiang University, Hangzhou 310006, China)
Bortezomib is a new proteasome inhibitor. Clinical studies demonstrat that bortezomib plays role in the treatment for relapsed, refractory and initially treated multiple myeloma. Clinical progress on bortezomib in the treatment for multiple myeloma was reviewed.
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.